Role of Unani Medicines in Cancer Control and Management

Author(s): Imran Ali*, Mohd. Suhail, Mohd. Farooq Naqshbandi, Mohd. Fazil, Bilal Ahmad, Ahmad Sayeed.

Journal Name: Current Drug Therapy

Volume 14 , Issue 2 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Cancer is a havoc and killer disease. Several ways including allopathic chemotherapy have been used in the cancer treatment. Allopathic chemotherapy has several limitations and side effects. Unani medicine is also one of the therapies to cure cancer.

Objective: In this type of treatment, herbal drugs are used for the treatment and prevention of cancer. The main attractive thing about herbal drug is no side effect as compared to allopathic chemotherapy.

Methods: Actually, herbal drugs are the extracts of medicinal plants. The plant extracts are obtained by crushing and heating the main part of the plants; showing anticancer activity. The main plants used in the treatment of cancer are oroxylum indicum, dillenia indica, terminalia arjuna etc.

Results: Mainly the cancers treated are of digestive system, breast, cervical, brain, blood, bone, lungs, thyroid, uterine, bladder, throat etc.

Conclusion: The present review article discusses the importance of Unani system of medicine for the treatment of cancer. Besides, the future perspectives of Unani medicine in cancer treatment are also highlighted.

Keywords: Cancer, Unani medicines, mechanism of action, future challenges, perspectives, allopathic chemotherapy.

[1]
Ali I. Nano drugs: novel agents for cancer chemo-therapy. Curr Cancer Drug Targets 2011; 11(2): 130.
[2]
Ali I, Aboul-Enein HY, Gupta VK. Nano chromatography and capillary electrophoresis: pharmaceutical and environmental analyses. In: Wiley & Sons. Hoboken 2009.
[3]
Ali I, Wani WA, Haque A, Saleem K. Glutamic acid and its derivatives: candidates for rational design of anticancer drugs. Future Med Chem 2013; 5(8): 961-78.
[4]
Ali I, Haque A, Saleem K, Hsieh MF. Curcumin-I Knoevenagel’s condensates and their Schiff’s bases as anticancer agents: synthesis, pharmacological and simulation studies. Bioorg Med Chem 2013; 21(13): 3808-20.
[5]
Ali I, Wani WA, Saleem K, Haque A. Platinum compounds: a hope for future cancer chemotherapy. Anticancer Agents Med Chem 2013; 13(2): 296-306.
[6]
Ali I, Wani WA, Saleem K, Haque A. Thalidomide: a banned drug resurged into future anticancer drug. Curr Drug Ther 2012; 7: 13-23.
[7]
Ali I, Wani WA, Saleem K. Cancer scenario in India with future perspectives. Cancer Ther 2011; 8: 56-70.
[8]
Ali I, Saleem K, Aboul-Enein HYA. Rather. Social aspects of cancer genesis. Cancer Ther 2011; 8: 6-14.
[9]
Ali I. Rahis-Uddin, Salim K, Rather MA, Wani WA, Haque A. Advances in nano drugs for cancer chemotherapy. Curr Cancer Drug Targets 2011; 11(2): 135-46.
[10]
Ali I. Rahisuddin, Kishwar S, Haque A, Azzouni AE. Natural products: human friendly anti-cancer medications. J Egyp Pharm 2010; 9: 133-79.
[11]
Kishwar S, Waseem AW, Ashanul H, et al. Synthesis, DNA binding, hemolysis assays and anticancer studies of copper (II), nickel (II) and iron (III) complexes of a pyrazolinebased ligand. Fut Med Chem 2013; 5: 135-46.
[12]
Ali I, Haque A, Wani WA, Saleem K, Al Za’abi M. Analyses of anticancer drugs by capillary electrophoresis: a review. Biomed Chromatogr 2013; 27(10): 1296-311.
[13]
Ali I, Suhail M, Lone MN, Alothman ZA, Alwarthan A. Chiral resolution of multichiral center racemates by different modalities of chromatography. J Liq Chromat Rel Techn 2016; 39: 435-44.
[14]
Ali I, Wani W, Saleem K, Hsieh MF. Anticancer metallodrugs of glutamic acid sulphonamides: in silico, DNA binding, hemolysis and anticancer studies. RSC Advances 2014; 4: 29629-41.
[15]
Ali I. Nano anti-cancer drugs: pros and cons and future perspectives. Curr Cancer Drug Targets 2011; 11(2): 131-4.
[16]
Ali I, Aboul-Enein HY, Ghanem A. Enantioselective toxicity and carcinogenesis. Curr Pharm Anal 2005; 1: 109-25.
[17]
Ali I, Aboul-Enein HY. Instrumental methods in metal ions speciation: Chromatography, Capillary Electrophoresis and Electrochemistry. New York, USA: Taylor& Francis Ltd. 2006.
[18]
Ali I, Lone MN, Suhail M, Mukhtar SD, Asnin L. Advances in Nanocarriers for Anticancer Drugs Delivery. Curr Med Chem 2016; 23(20): 2159-87.
[19]
Manzur A, Oluwasanmi A, Moss D, Curtis A, Hoskins C. Nanotechnologies in pancreatic cancer therapy Pharmaceutics 2017; 9(4): 39.
[20]
Chen J, Wang Y, Liu T. Photodynamic efficiency of new porphyrin-typed drug on HGC27 and MGC803 cells. Guoji Shengwu Yixue Gongcheng Zazhi 2011; 34: 154-7.
[21]
Boccellino M, Pedata P, Castiglia L, et al. Doxorubicin can penetrate nitrile gloves and induces apoptosis in keratinocytes cell lines. Toxicol Lett 2010; 197(2): 61-8.
[22]
Ali I, Suhail M, Sanagi MM, Aboul-Enein HY. Ionic Liquids in HPLC and CE: A Hope for Future. Crit Rev Anal Chem 2017; 47(4): 332-9.
[23]
Rosen O, Schymanietz C, Holzel F. Antiproliferative, cytotoxic and recovery effects in tumor-cell cultures treated with synthetic phospholipids. Int J Oncol 1994; 5(3): 517-23.
[24]
Tonk M, Vilcinskas A, Rahnamaeian M. Insect antimicrobial peptides: potential tools for the prevention of skin cancer. Appl Microbiol Biotechnol 2016; 100(17): 7397-405.
[25]
Xu H, Zhao R. Application of leech maggot protein in preparation of anti-pancreatic cancer drug. Faming Zhuanli Shenqing 2015. CN 104622908 A 20150520 2015
[26]
Anzar A, Shamim A, Tanwir A, Abdul A. Cancer (Sartan) and Its Management in Unani (Greco-Arab) System of Medicine. Intern J Pharm India 2013; 1: 612-30.
[27]
Aboul-Enein HY, Ali I. Macrocyclic antibiotics as effective chiral selectors for enantiomeric resolution by liquid chromatography and capillary electrophoresis. Chromatographia 2000; 52: 679-91.
[28]
Ali I, Kumerer K, Aboul-Enein HY. Mechanistic principles in chiral separations using liquid chromatography and capillary electrophoresis. Chromatographia 2006; 63: 295-307.
[29]
Ali I, Aboul-Enein HY, Gupta VK. Nanochromatography and nanocapillary electrophoresis: pharmaceutical and environmental analyses. John Wiley & Sons 2009.
[30]
Ali I, Gaitonde VD, Aboul-Enein HY, Hussain A. Chiral separation of β-adrenergic blockers on CelluCoat column by HPLC. Talanta 2009; 78(2): 458-63.
[31]
Aboul-Enein HY, Ali I. Determination of tadalafil in pharmaceutical preparation by HPLC using monolithic silica column. Talanta 2005; 65(1): 276-80.
[32]
Ali I, Khan TA, Asim M. Removal of arsenic from water by electrocoagulation and electrodialysis techniques. Separ Purif Rev 2011; 40: 25-42.
[33]
Aboul-Enein HY, Ali I. Optimization strategies for HPLC enantioseparation of racemic drugs using polysaccharides and macrocyclic glycopeptide antibiotic chiral stationary phases. Farmaco 2002; 57(7): 513-29.
[34]
Ali I, Aboul-Enein HY. Impact of immobilized polysaccharide chiral stationary phases on enantiomeric separations. J Sep Sci 2006; 29(6): 762-9.
[35]
Ali I, Saleem K, Hussain I, Gaitonde VD, Aboul‐Enein HY. Polysaccharides chiral stationary phases in liquid chromatography. Sep & Pur Rev 2009; 38: 97-147.
[36]
Ali I, Gupta VK, Aboul-Enein HY, Hussain A. Hyphenation in sample preparation: advancement from the micro to the nano world. J Sep Sci 2008; 31(11): 2040-53.
[37]
Ali I, Gupta VK, Aboul-Enein HY, Singh P, Sharma B. Role of racemization in optically active drugs development. Chirality 2007; 19(6): 453-63.
[38]
Ali I, Jain CK. Advances in arsenic speciation techniques. Int J Environ Anal Chem 2004; 84: 947-64.
[39]
Ali I, Aboul-Enein HY. Speciation of arsenic and chromium metal ions by reversed phase high performance liquid chromatography. Chemosphere 2002; 48(3): 275-8.
[40]
Aboul-Enein HY, Ali I. Studies on the effect of alcohols on the chiral discrimination mechanisms of amylose stationary phase on the enantioseparation of nebivolol by HPLC. J Biochem Biophys Methods 2001; 48(2): 175-88.
[41]
Ali I, Gupta VK, Khan TA, Asim M. Removal of arsenate from aqueous solution by electro-coagulation method using Al-Fe electrodes. Int J Electrochem Sci 2012; 7: 1898-907.
[42]
Gupta VK, Ali I. Environmental water: advances in treatment, remediation and recycling. The Netherlands: Elsevier 2012.
[43]
Ali I, Naim L, Ghanem A, Aboul-Enein HY. Chiral separations of piperidine-2,6-dione analogues on Chiralpak IA and Chiralpak IB columns by using HPLC. Talanta 2006; 69(4): 1013-7.
[44]
Ali I, Al-Othman ZA, Alwarthan A, Asim M, Khan TA. Removal of arsenic species from water by batch and column operations on bagasse fly ash. Environ Sci Pollut Res Int 2014; 21(5): 3218-29.
[45]
Aboul-Enein HY, Ali I. Comparative study of the enantiomeric resolution of chiral antifungal drugs econazole, miconazole and sulconazole by HPLC on various cellulose chiral columns in normal phase mode. J Pharm Biomed Anal 2002; 27(3-4): 441-6.
[46]
Ali I, Al-Othman ZA, Alwarthan A. Green synthesis of iron nano-impregnated adsorbent for fast removal of fluoride from water. J Mol Liq 2015; 211: 457-65.
[47]
Ali I. Role of Unani medicine in cancer control and management, 12thAnnual Pharma Middle East Congress. J Pharma Care Health Sys 2017; 2017: 4.
[48]
Ali I, Alothman ZA, Alwarthan A. Synthesis of composite iron nano adsorbent and removal of ibuprofen drug residue from water. J Mol Liq 2016; 219: 858-64.
[49]
Ali I, Aboul-Enein HY. Enantioseparation of some clinically used drugs by HPLC using cellulose Tris (3, 5-dichlorophenylcarbamate) chiral stationary phase. Biomed chromat 17: 113-7.2003;
[50]
Ali I, Al-Othman ZA, Alwarthan A. Molecular uptake of congo red dye from water on iron composite nano particles. J Mol Liq 2016; 224: 171-6.
[51]
Ali I, Khan TA, Asim M. Removal of arsenate from groundwater by electrocoagulation method. Environ Sci Pollut Res Int 2012; 19(5): 1668-76.
[52]
Ali I, Suhail M, Al-Othman ZA, Alwarthan A, Aboul-Enein HY. Enantiomeric resolution of multiple chiral centres racemates by capillary electrophoresis. Biomed Chromatogr 2016; 30(5): 683-94.
[53]
Aboul-Enein HY, Ali I. HPLC enantiomeric resolution of nebivolol on normal and reversed amylose based chiral phases. Pharmazie 2001; 56(3): 214-6.
[54]
Ali I. AL-Othman Z. A; Green synthesis of functionalized iron nano particles and molecular liquid phase adsorption of ametryn from water. J Mol Liq 2016; 221: 1168-74.
[55]
Ali I, Sanagi MM, Aboul-Enein HY. Advances in chiral separations by nonaqueous capillary electrophoresis in pharmaceutical and biomedical analysis. Electrophoresis 2014; 35(7): 926-36.
[56]
Ali I, Suhail M, Asnin L. Chiral separation of quinolones by liquid chromatography and capillary electrophoresis. J Sep Sci 2017; 40(14): 2863-82.
[57]
Ali I, Gupta VK, Aboul-Enein HY. Chirality: a challenge for the environmental scientists. Curr sci-bangalore 84: 152-6.
[58]
Ali I, Al-Othman ZA, Alwarthan A. Uptake of pantoprazole drug residue from water using novel synthesized composite iron nano adsorbent. J Mol Liq 2016; 218: 465-72.
[59]
Al-Othman ZA, Al-Warthan A, Ali I. Advances in enantiomeric resolution on monolithic chiral stationary phases in liquid chromatography and electrochromatography. J Sep Sci 2014; 37(9-10): 1033-57.
[60]
Ali I, Wani WA, Khan A, et al. Synthesis and synergistic antifungal activities of a pyrazoline based ligand and its copper (II) and nickel (II) complexes with conventional antifungals. Microb pathogen 2012; 53: 66-73.
[61]
Aboul-Enein HY, Ali I. Comparison of the chiral resolution of econazole, miconazole, and sulconazole by HPLC using normal-phase amylose CSPs. Fresenius J Anal Chem 2001; 370(7): 951-5.
[62]
Ali I, Al-Othman ZA, Hussain A, Saleem K, Aboul-Enein HY. Chiral separation of β-adrenergic blockers in human plasma by SPE-HPLC. Chromatographia 2011; 73: 251-6.
[63]
Ali I, Al-Othman ZA, Alwarthan A. Uptake of propranolol on ionic liquid iron nanocomposite adsorbent: Kinetic, thermodynamics and mechanism of adsorption. J Mol Liq 2017; 236: 205-3.
[64]
Ali I, Al-Othman ZA, Al-Warthan A, Asnin L, Chudinov A. Advances in chiral separations of small peptides by capillary electrophoresis and chromatography. J Sep Sci 2014; 37(18): 2447-66.
[65]
Ali I, Lone MN, Suhail M. ZA AL-Othman; A Alwarthan; Enantiomeric resolution and simulation studies of four enantiomers of 5-bromo-3-ethyl-3-(4-nitrophenyl)-piperidine-2, 6-dione on a Chiralpak IA column. RSC Advances 2016; 6: 14372-80.
[66]
Aboul-Enein HY, Ali I, Gübitz G, Simons C, Nicholls PJ. HPLC enantiomeric resolution of novel aromatase inhibitors on cellulose- and amylose-based chiral stationary phases under reversed phase mode. Chirality 2000; 12(10): 727-33.
[67]
Ali I, Al-Othman ZA, Nagae N, Gaitonde VD, Dutta KK. Recent trends in ultra-fast HPLC: new generation superficially porous silica columns. J Sep Sci 2012; 35(23): 3235-49.
[68]
William D. City of Djinns: A Year in Delhi 1994.
[69]
Rahman HSZ. 2001.
[70]
Ali I, Al-Othman ZA, Al-Za’abi M. Superficially porous particles columns for super fast HPLC separations. Biomed Chromatogr 2012; 26(8): 1001-8.
[71]
Ali I, Suhail M, Alothman ZA, Alwarthan A. Chiral separation and modeling of baclofen, bupropion, and etodolac profens on amylose reversed phase chiral column. Chirality 2017; 29(7): 386-97.
[72]
Ali I, Singh P, Aboul-Enein HY, Sharma B. Chiral analysis of ibuprofen residues in water and sediment. Anal Lett 2009; 42: 1747-60.
[73]
Alajmi MF, Hussain A, Suhail M, et al. Chiral HPLC Separation and Modeling of Four Stereomers of DL-Leucine-DL-Tryptophan Dipeptide on Amylose Chiral Column. Chirality 2016; 28(9): 642-8.
[74]
Aboul-Enein HY, Ali I. Enantiomeric resolution of some imidazole antifungal agents on chiralpak WH chiral stationary phase using HPLC. Chromatographia 2011; 54: 200-2.
[75]
Ali I, Al-Othman ZA, Alwarthan A. Sorption, kinetics and thermodynamics studies of atrazine herbicide removal from water using iron nano-composite material. Int J Environ Sci Technol 2016; 13: 733-42.
[76]
Ali I, Asim M, Khan TA. Arsenite removal from water by electro-coagulation on zinc-zinc and copper-copper electrodes. Int J Environ Sci Technol 2013; 10: 377-84.
[77]
Ali I, Wani WA, Saleem K, Hseih MF. Design and synthesis of thalidomide based dithiocarbamate Cu (II), Ni (II) and Ru (III) complexes as anticancer agents. Polyhedron 2013; 56: 134-43.
[78]
Ali I, Saleem K, Gaitonde VD, Aboul-Enein HY, Hussain I. Chiral separations of some β-adrenergic agonists and antagonists on AmyCoat column by HPLC. Chirality 2010; 22(1): 24-8.
[79]
Ali I, Aboul-Enein HY, Gaitonde VD, Singh P, Rawat MSM, Sharma B. Chiral separations of imidazole antifungal drugs on AmyCoat RP column in HPLC. Chromatographia 2009; 70: 223-7.
[80]
Ali I, Gupta VK, Aboul-Enein HY. Metal ion speciation and capillary electrophoresis: application in the new millennium. Electrophoresis 2005; 26(21): 3988-4002.
[81]
Ali I, Gupta VK, Aboul-Enein HY. Chiral resolution of some environmental pollutants by capillary electrophoresis. Electrophoresis 2003; 24(9): 1360-74.
[82]
Jain CK, Ali I. Ground water contamination and health hazards by some of the most commonly used pesticides. Curr Sci 1998; 75: 1011-4.
[83]
Ali I, Saleem K, Wesselinova D, Haque A. Synthesis, DNA binding, hemolytic, and anti-cancer assays of curcumin I-based ligands and their ruthenium (III) complexes. Med Chem Res 2013; 22: 1386-98.
[84]
Ali I, Gaitonde VD, Aboul-Enein HY. Monolithic silica stationary phases in liquid chromatography. J chromat sci 47: 432-2.2009;
[85]
Ali I, Nadeem Lone M, Al-Othman Z A. Heterocyclic scaffolds: centrality in anticancer drug development. Curr drug targ 16: 711-34.2015;
[86]
Ali I, Wani WA, Saleem K, Wesselinova D. Syntheses, DNA binding and anticancer profiles of L-glutamic acid ligand and its copper(II) and ruthenium(III) complexes. Med Chem 2013; 9(1): 11-21.
[87]
Ali I, Suhail M, Alothman ZA, Badjah AY. Stereoselective interactions of profen stereomers with human plasma proteins using nano solid phase micro membrane tip extraction and chiral liquid chromatography. Separ Purif Tech 2018; 197: 336-44.
[88]
Ali I, Suhail M, Asnin L, Aboul-Enein HY. Reverse Elution Order of β-Blockers in Chiral Separation. J Liq Chromat & Rel Techn 2017; 40: 435-41.
[89]
Sreejayan RM, Rao MN. Nitric oxide scavenging by curcuminoids. J Pharm Pharmacol 1997; 49(1): 105-7.
[90]
Ali I, Saleem K. Rahis-uddin; Natural Products: Human Friendly Anti-Cancer Medications. Egyp Pharm J 2010; 9: 133-79.
[91]
Sreejayan, Rao MN. Curcuminoids as potent inhibitors of lipid peroxidation. J Pharm Pharmacol 1994; 46(12): 1013-6.
[92]
Jha K, Garg A, Narang R, Das S. Hirudotherapy in medicine and dentistry. J Clin Diagn Res 2015; 9(12): ZE05-7.
[93]
Ko S G, Lee G, Cho S G. Pharmaceutical composition for preventing or treating cancer comprising fraction of mixed herbal extract as active ingredient Repub. Korean Kongkae Taeho Kongbo 2017; KR 2017109703 A 20171010 2017.
[94]
Nisa M, Akbar S, Tariq M, Hussain Z. Effect of Cuscuta chinensis water extract on 7,12-dimethylbenz[a]anthraceneinduced skin papillomas and carcinomas in mice. J ethnopharm 18: 21-31.1986;
[95]
Sumathi C S. The Biological Potentialsof Indian Traditional Medicine, Curcumin for Treating Human Diseases. Cardiovashematolo agents in med chem (2017) 2017.
[96]
Singh P, Guleri R, Singh V, et al. Biotechnological interventions in Withania somnifera (L.) Dunal. Biotech gen engin rev 31: 1-20.2015;
[97]
Patil J B, Kim J, Jayaprakasha G K. Berberine induces apoptosis in breast cancer cells (MCF-7) through mitochondrial- dependent pathway. Europ j pharm 645: 70-8.2010;
[98]
Haniadka R, Rajeev A G, Palatty P L, Arora R, Baliga M S. ingiber officinale (ginger) as an anti-emetic in cancer chemotherapy: a review. J altern and complem med (New York, NY) 18:: 440-.2012;
[99]
Zhang T. Containing isodon striatus of chinese medicine powder for preventing tumor. Faming Zhuanli Shenqing 2017.
[100]
Yang S, Chen Y, Tang M. A detection method for traditional chinese medicine for treating cancer. Faming Zhuanli Shenqing 2015; CN 104569169 A 20150429 2015.
[101]
Mei S. An anti-cancer traditional chinese medicine and its preparation method. Faming Zhuanli Shenqing 2015; CN 104547896 A 20150429 2015.
[102]
Ren Y. A therapeutic composition for treating cancer. CN 104547106 A 20150429 2015.
[103]
Anonymous . The Wealth of India (Raw Materials). In: C S I R New Delhi. 1950; Vol. II: pp. 406-7.
[104]
Anis E, Anis I, Ahmed S, et al. Alpha-glucosidase inhibitory constituents from Cuscuta reflexa. Chem Pharm Bull (Tokyo) 2002; 50(1): 112-4.
[105]
Faiyyaz BI, Rajesh JO, Trushal VC, Kapil G. In Vitro Antimicrobial Activity of Cuscuta Reflexa Roxb. Int Res J of Pharmacy 2011; 2: 214-6.
[106]
Mateen A, Suresh PVK. Ahmed p. Evaluation of antibacterial activity of Cuscuta reflexa and Abutilon indicum. Int J Pharma Bio Sci 2011; 2: 355-61.
[107]
Gupta M, Mazumder UK, Pal D, Bhattacharya S, Chakrabarty S. Studies on brain biogenic amines in methanolic extract of Cuscuta reflexa Roxb. and Corchorus olitorius Linn. seed treated mice. Acta Pol Pharm 2003; 60(3): 207-10.
[108]
Borole SP, Oswal RJ, Antre RV, Kshir S, Bagul YR. Evaluation of antiepileptic activity of Cuscuta reflexa Roxb. Res J Pharm Biol Chem Sci 2011; 2: 657-63.
[109]
Mahmood N, Piacente S, Burke A, Khan A, Pizza C. Constituents of Cuscuta reflexa are anti-HIV agents. Antivir Chem Chemother 1997; 8: 70-4.
[110]
Chatterjee D, Sahu KR, Jha KA, Dwlvedl J. Evaluation of Antitumor Activity of Cuscuta Reflexa Roxb (Cuscutaceae) Against Ehrlich Ascites Carcinoma in Swiss Albino Mice. Trop J Pharm Res 2011; 10: 447-54.
[111]
Suresh V, Sruthi V, Padmaja B, Asha VV. In vitro anti-inflammatory and anti-cancer activities of Cuscuta reflexa Roxb. J Ethnopharmacol 2011; 134(3): 872-7.
[112]
Udavant PB, Satyanarayana SV, Upasani CD. Preliminary screening of Cuscuta reflexa stems for anti-inflammatory and cytotoxic activity. Asian Pac J Trop Biomed 2012; 2(3): S1303-7.
[113]
Costa-Lotufo LV, Khan MTH, Ather A, et al. Studies of the anticancer potential of plants used in Bangladeshi folk medicine. J Ethnopharmacol 2005; 99(1): 21-30.
[114]
Asolkar L V, Kakkar K K, Chakre O J. Second Supplement to Glossary of Indian Medicinal Plants with an active principles Part-I (A- K) 2481992
[115]
Kelker SL, Phadke CP, Marina S. Isolation of compound from Cuscuta reflexa. Indian J Chem Sect 1984; 23: 458-9.
[116]
Niwa M, Lwadare Y, Yang-Chang W, Hirata Y. Two New Phenylpropanoid Glycosides from Wikstroemia sikokiana. Chem Pharm Bull (Tokyo) 1988; 36: 1158-61.
[117]
Uddin SJ, Shilpi JA, Middleton M, et al. Swarnalin and cis-swarnalin, two new tetrahydrofuran derivatives with free radical scavenging activity, from the aerial parts of Cuscuta reflexa. Nat Prod Res 2007; 21(7): 663-8.
[118]
Montgomery EA. Cancer by organ site; oesophageal cancer.. In: Stewart BW, Wild CP, Eds Word Cancer Report 2014. Cedex, France: IARC Publications 2014; pp. 374-83.
[119]
Ferri F. Ferri's clinical advisor Elsevier 2017.
[120]
Rebecca S, Carol D, Ahmedin J. Colorectal Cancer Statistics 2014. CA Cancer J Clin 2014; 64: 104-17.
[121]
General Information About Colon Cancer NCI. 2014.
[122]
Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379(9822): 1245-55.
[123]
Miller RC, Iott MJ, Corsini MM. Review of Adjuvant Radiochemotherapy for Resected Pancreatic Cancer and Results From Mayo Clinic for the 5th JUCTS Symposium. Int J Rad Oncol Biol Phys. 75:: 364-8.
[124]
What is Cancer? Defining Cancer. National Cancer Institute, National Institutes of Health 2014.
[125]
Pancreatic Cancer Treatment. (PDQ®) Patient Version National Cancer Institute. National Institutes of Health 2014.
[126]
Wang X, Wu C, Ma F. Chinese herbal “three-gen” pills for treating esophageal cancer and its preparation method Faming Zhuanli Shenqing 2017 2017.
[127]
Wang X, Wang G, Ma F. The hui nationality traditional chinese medicine flower root gastric cancer prevention tablet and its preparation method Faming Zhuanli Shenqing 2017 2017.
[128]
Wang X, Wang G, Ma F. Hui nationality chinese herbal medicine smilax bockii warb tablet for treating esophagus cancer and its preparation method Faming Zhuanli Shenqing 2017; CN 106668721 A 20170517 2017.
[129]
Wang X, Ma G, Ma F. Chinese herbal medicine sophorae tonkinensis -curcuma zedoary oral liquid for treating esophageal cancer and its preparation method. Faming Zhuanli Shenqing 2017; CN 106668718 A 20170517 2017.
[130]
Wang X, Wang G, Ma F. The hui chinese herbal medicine red bean pill for treatment of stomach cancer and its preparation method. Faming Zhuanli Shenqing 2017; CN 106668730 A 20170517 2017.
[131]
Wang X, Wang G, Ma F. Hui nationality chinese herbal medicine particle containing red bean for treating gastric cancer and its preparation method. Faming Zhuanli Shenqing 2017; CN 106668701 A 20170517 2017.
[132]
Yang H. A composition for treatment of esophageal cancer and laryngeal cancer traditional chinese medicine. Faming Zhuanli Shenqing 2017; CN 106692674 A 20170524 2017.
[133]
Wang X, Wang G, Ma F. A hui nationality traditional chinese medicine shuzi weiaikang tablet for treating gastric cancer and its preparation method. Faming Zhuanli Shenqing 2017; CN 106668740 A 20170517 2017.
[134]
Wang X, Wu C, Ma F. Hui population chinese herbal particle made from levant cotton root, subprostrate sophora root and isodon amethystoides root and capable of treating esophagus cancer and its preparation method. Faming Zhuanli Shenqing 2017; CN 106668683 A 20170517 2017.
[135]
Ben-Arye E, Lavie O, Samuels N, et al. Safety of herbal medicine use during chemotherapy in patients with ovarian cancer: a "bedside-to-bench" appr Med Oncl (New York, NY, United States) 2017; 34: 1-6.
[136]
Pang D, Kong Q. Therapeutic composition for treating colon cancer after operation and preparation method thereof.In: Faming Zhuanli Shenqing. 2016.
[137]
Wang C. Treating colorectal cancer therapeutic preparation and application thereof. Faming Zhuanli Shenqing 2016; CN 105833018 A 20160810 2016.
[138]
Sun S, Huang Y, Xiu L. Anti-inflammatory oncolytic liver drugFaming Zhuanli Shenqing 2017; CN 106727823 A20170531 2017.
[139]
Wang X, Wang G, Ma F. Chinese herbal medicine of sagittaria sagittifolia liver cancer particle of hui nationality and its preparation method. Faming Zhuanli Shenqing 2017; CN 106668517 A 20170517 2017.
[140]
Liu X, Song L, Peng X, Zhou S. A method for preparing effective part of traditional chinese herbs composition for treating hepatocarcinom. Faming Zhuanli Shenqing 2015;CN 104586990 A 20150506 2015.
[141]
Sun Q. Treating pancreatic cancer drug and its preparation methodFaming Zhuanli Shenqing 2016; CN 105998958 A 20161012 2016.
[142]
Pang Q. Combine traditional chinese medicine for treating carcinoma of head of pancreas. Faming Zhuanli Shenqing 2016; CN 105535844 A 20160504 2016.
[143]
Qin C. Chinese medicine preparation for treating gastric cancer Faming Zhuanli Shenqing 2015; CN 104547866 A 20150429 2015.
[144]
Zheng H, Zhang J, Zhang H, Li N. A chinese medicinal composition for treating spleen and stomach weakness type gastric cancer medicine and preparation method thereof. Faming Zhuanli Shenqing 2015; CN 104547819 A 20150429 2015.
[145]
Rebecca S, Jiemin M, Zhaohui Z, Ahmedin J. Cancer Statistics 2014. CA Cancer J Clin 2014; 64: 9-29.
[146]
Breast Cancer Treatment (PDQ®). NCI.. 2014.
[147]
Kang L. A kind of pharmaceutical composition for treating breast cancer and its preparation method, preparation and application Faming Zhuanli Shenqing 2017; CN 107213350 A 20170929 2017.
[148]
Wang X, Wang G, Zhao P. Hui nationality chinese medicine bufonid breast cancer-treating granule and its preparation method Faming Zhuanli Shenqing 2017; CN 106668710 A 20170517 2017.
[149]
Liu W. Drug for treating breast cancer. Faming Zhuanli Shenqing 2015; CN 104586999 A 20150506 2015.
[150]
Hua Z, Zhu T, Liu S, Sun N, Wang J, Xu X. A kind of plaster for treatment of mammary gland disease and preparation method thereof. Faming Zhuanli Shenqing 2017; CN 107198762 A 20170926 2017.
[151]
Kokka F, Bryant A, Brockbank E, Jeyarajah A. Surgical treatment of stage IA2 cervical cancer. Cochrane Database Syst Rev 2014; 5CD010870
[152]
Zheng M. A kind of pharmaceutical composition for treating cervical cancer and preparation method thereof, preparation and application . Faming Zhuanli Shenqing 2017; CN 107213309 A 20170929 2017.
[153]
Bi Wang, Huang Z, Zeng Z. A kind of chinese medicine composition for treating cervical cancer and preparation method thereof Faming Zhuanli Shenqing 2017; CN 106728762 A 20170531 2017.
[154]
Xi Wang, Wang G, Ma F. Hui nationality pill containing chinese medicine radix scutellariae for treating breast cancer and its preparation method Faming Zhuanli Shenqing 2017; CN 106668493 A 20170517 2017.
[155]
General Information About Adult Brain Tumors NCI. 2014.
[156]
Adult Brain Tumors Treatment NCI. 2014.
[157]
Longo DL. “369 Seizures and Epilepsy”. Harrison’s principles of internal medicine. In: McGraw-Hill. 18th ed. 2012; p. 3258.
[158]
General Information About Adult Brain Tumors NCI. 2014.
[159]
Cao G, Cao D. Treatment of anti-brain cancer therapeutic composition and preparation method thereof Faming Zhuanli Shenqing 2017; CN 107184936 A 20170922 2017.
[160]
Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114(5): 937-51.
[161]
World Cancer Report 2014. World Health Organization.2014.. pp Chapter 513 ISBN 9283204298 2014.
[162]
Zhang L. Chinese herbal medicine formula for radical treatment of cancer and leukemia Faming Zhuanli Shenqing Faming Zhuanli Shenqing 2017; CN 107115495 A 20170901 2017.
[163]
Wang X, Wang G, Zhao P. Chinese herbal medicine of six ingredients blood cancer tablets of hui nationality and its preparation method Faming Zhuanli Shenqing Faming Zhuanli Shenqing 2017; CN 106668519 A 20170517 2017.
[164]
Wang X, Wang G, Zhao P. Six chinese herbal medicinemixed oral liquid for treating blood cancer and its preparation method Faming Zhuanli Shenqing 2017. CN 106668535 A 20170517 2017
[165]
Wang X, Wang Y, Ma F. Hui nationality chinese herbal medicine liuwei pill for treatment of leukemia and its preparation method. Faming Zhuanli Shenqing 2017. CN 106668526 A 20170517 2017.
[166]
Wang X, Wang G, Zhao N. Hui nationality tablet containing chinese herbal medicine curcuma zedoary and sarcandra for treating leukemia and its preparation method Faming Zhuanli Shenqing 2017. CN 106668726 A 20170517 2017.
[167]
Zhou M. A chinese medicine formulation for treating skin diseases and its tumors Faming Zhuanli Shenqing 2015. CN 104940310 A 20150930 2015.
[168]
Li Y. Questions and Answers about Bone Cancer" (PDF). Centers for Disease Control and Prevention 2017.
[169]
Li Y. Treating bone tumor drug and its preparation methodFaming Zhuanli Shenqing 2017. CN 106798857 A 20170606 2017.
[170]
Carcinoma Lung. Lung Carcinoma: Tumors of the Lungs. Merck Manual Professional Edition, Online edition 2007.
[171]
Non-Small Cell Lung Cancer Treatment -Patient Version(PDQ®) NCI. 2015.
[172]
Horn L, Lovly CM, Johnson DH. Chapter 107: Neoplasms of the lung. 2015.
[173]
Wu B. A kind of chinese medicine composition treating lung cancer and its preparation method and application Faming Zhuanli Shenqing Faming Zhuanli Shenqing (2017), CN 106729510 A 20170531 2017.
[174]
Liu X. A chinese medicine composition for treating lung cancerFaming Zhuanli Shenqing 2015. CN 104547977 A 20150429 2015.
[175]
Benjamin R, Luc M, Louise D. The Thyroid Cancer Epidemic 2017 Perspective. Curr Opin Endocrinol Diabetes Obes 2017; 24(5): 332-6.
[176]
World Health Organization (WHO), Cancer Fact Sheet (N 297). 2011.
[177]
Defining Cancer National Cancer Institute 2014.
[178]
Zhang L. Treating thyroid cancer drug and its preparation method Faming Zhuanli Shenqing (2017). CN 106692889 A 20170524 2017.
[179]
Li Sun. A composition for treating phlegm dampness coagulation type thyroid cancer traditional chinese medicine Faming Zhuanli Shenqing. Faming Zhuanli Shenqing (2016). CN 106138934 A 20161123 2016
[180]
Hoffman B. Endometrial Cancer” Williams gynecology. 2nd ed. New York: McGraw-Hill Medical 2011.
[181]
Hoffman BL. Cervical Cancer” Williams gynecology. 2nd ed. New York: McGraw-Hill Medical 2011.
[182]
Luo X. A kind of chinese medicine composition for treatment of uterine cancer and preparation method thereof Faming Zhuanli Shenqing 2017. CN 106389938 A 20170215 2017
[183]
Bladder Cancer Treatment (PDQ®). NCI, . 2019.
[184]
Abdel-Razeq H, Attiga F, Mansour A. Cancer care in Jordan. Hematol Oncol Stem Cell Ther 2015; 8(2): 64-70.
[185]
Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute 2013.http://seer.cancer.gov/csr/1975_2010/ Accessed on June 17, 2013.
[186]
Chen Y, Chen J. A composition for treating bladder cancer and prostate cancer chinese herbal medicine Faming Zhuanli Shenqing Archived from the original on 25 June 2014 2016.
[187]
Bauman JE, Cohen E, Ferris RL, et al. Immunotherapy of Head and Neck Cancer: Emerging Clinical Trials From a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer 2017; 123(7): 1259-7.
[188]
Gao S, Wang A. A chinese medicinal composition for treating throat cancerFaming Zhuanli Shenqing 2015. CN 104740400 A 20150701 2015
[189]
Syed DN, Khan N, Afaq F, Mukhtar H. Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiol Biomarkers Prev 2007; 16(11): 2193-203.
[190]
Nelson PS, Montgomery B. Unconventional therapy for prostate cancer: good, bad or questionable? Nat Rev Cancer 2003; 3(11): 845-58.
[191]
Gupta S, Hussain T, Mukhtar H. Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys 2003; 410(1): 177-85.
[192]
Garbisa S, Biggin S, Cavallarin N, Sartor L, Benelli R, Albini A. Tumor invasion: molecular shears blunted by green tea. Nat Med 1999; 5(11): 1216.
[193]
Jatoi A, Ellison N, Burch PA, et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003; 97(6): 1442-6.
[194]
Chen S, Ruan Q, Bedner E, et al. Effects of the flavonoid baicalin and its metabolite baicalein on androgen receptor expression, cell cycle progression and apoptosis of prostate cancer cell lines. Cell Prolif 2001; 34(5): 293-304.
[195]
Chen L, Stacewicz-Sapuntzakis M, Duncan C, et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst 2001; 93(24): 1872-9.
[196]
DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 1998; 339(12): 785-91.
[197]
Richardson MA, White JD. Complementary/alternative medicine and cancer research. A national initiative. Cancer Pract 2000; 8(1): 45-8.
[198]
Gerber B, Scholz C, Reimer T, Briese V, Janni W. Complementary and alternative therapeutic approaches in patients with early breast cancer: a systematic review. Breast Cancer Res Treat 2006; 95(3): 199-209.
[199]
Sakaida I, Tsuchiya M, Kawaguchi K, Kimura T, Terai S, Okita K. Herbal medicine Inchin-ko-to (TJ-135) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. J Hepatol 2003; 38(6): 762-9.
[200]
Lin HJ, Chen JY, Lin CF, et al. Hepatoprotective effects of Yi Guan Jian, an herbal medicine, in rats with dimethylnitrosamine-induced liver fibrosis. J Ethnopharmacol 2011; 134(3): 953-60.
[201]
Lin X, Zhang S, Huang Q, et al. Protective effect of Fufang-Liu-Yue-Qing, a traditional Chinese herbal formula, on CCl4 induced liver fibrosis in rats. J Ethnopharmacol 2012; 142(2): 548-56.
[202]
Lv J, Zhao Z, Chen Y, et al. The chinese herbal decoction danggui buxue tang inhibits angiogenesis in a rat model of liver fibrosis 2012.
[203]
Wang TL, Wang BE, Zhang HH, Liu X, Duan ZP, Zhang J. Pathological study of the therapeutic effect on HBV-related liver fibrosis with herbal compound 861. Chin J Gastroenterol Hepatol 1998; 7: 148-53.
[204]
Wangand HJ, Wang BEW. Long-term follow-upresult of compound Dan Shen granule (861 Chong Fu Ji) in treating hepatofibrosis. Chinese J Integr Tradi Weste Medic 1995; 5: 4-5.
[205]
Kayano K, Sakaida I, Uchida K, Okita K. Inhibitory effects of the herbal medicine Sho-saiko-to (TJ-9) on cell proliferation and procollagen gene expressions in cultured rat hepatic stellate cells. J Hepatol 1998; 29(4): 642-9.
[206]
Sakaida I, Matsumura Y, Akiyama S, Hayashi K, Ishige A, Okita K. Herbal medicine Sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. J Hepatol 1998; 28(2): 298-306.
[207]
Lee JK, Kim JH, Shin HK. Therapeutic effects of the oriental herbal medicine Sho-saiko-to on liver cirrhosis and carcinoma. Hepatol Res 2011; 41(9): 825-37.
[208]
Stickel F, Schuppan D. Herbal medicine in the treatment of liver diseases. Dig Liver Dis 2007; 39(4): 293-304.
[209]
Morton JP, Mongeau ME, Klimstra DS, et al. Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc Natl Acad Sci USA 2007; 104(12): 5103-8.
[210]
Dijkgraaf G J P, Alicke B, Weinmann L, et al. mall molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Canc Res 71: 435-44.2011;
[211]
Feldmann G, Dhara S, Fendrich V, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 2007; 67(5): 2187-96.
[212]
Ernst E. Heavy metals in traditional Indian remedies. Eur J Clin Pharmacol 2002; 57(12): 891-6.
[213]
Shaw D, Leon C, Kolev S, Murray V. Traditional remedies and food supplements. A 5-year toxicological study (1991-1995). Drug Saf 1997; 17(5): 342-56.
[214]
Muzi G, Dell’omo M, Madeo G, Abbritti G, Caroli S. Arsenic poisoning caused by Indian ethnic remedies. J Pediatr 2001; 139(1): 169.
[215]
Itankar PR, et al. Estimation of arsenic content in some Ayurvedic formulations. Hamdard Med 2001; 19: 95-7.
[216]
Ernst E, Thompson Coon J. Heavy metals in traditional Chinese medicines: a systematic review. Clin Pharmacol Ther 2001; 70(6): 497-504.
[217]
Ko RJ. Adulterants in Asian patent medicines New Engl J Med 1998.
[218]
Koh HL, Woo SO. Chinese proprietary medicine in Singapore: regulatory control of toxic heavy metals and undeclared drugs. Drug Saf 2000; 23(5): 351-62.
[219]
Melchart D, et al. Quality assurance and evaluation of Chinese medicinal drugs in a hospital of traditional Chinese medicine in Germany: a five-year report. Altern Ther Health Med 2001; 7: S24.
[220]
Liang W, Lin SW, Yen KY, Yang LL. Metal element analysis of commercial Chinese herbal medicines. Taiwan Kexue 1998; 51: 37-56.
[221]
Ueng TH, Kang J, Wang HW, Lin PC. An overview of the toxicology of commonly used traditional Chinese medicine. Yao Wu Shi Pin Fen Xi 1997; 5: 241-63.
[222]
Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10(8): 789-99.
[223]
Jimeno A, Hidalgo M. Multitargeted therapy: can promiscuity be praised in an era of political correctness? Crit Rev Oncol Hematol 2006; 59(2): 150-8.
[224]
Sams-Dodd F. Target-based drug discovery: is something wrong? Drug Discov Today 2005; 10(2): 139-47.
[225]
Radulovic S, Bjelogrlic SK. Sunitinib, sorafenib and mTOR inhibitors in renal cancer. J BUON 2007; 12(Suppl. 1): S151-62.
[226]
Aggarwal BB, Surh YH, Shishodia S. The molecular targets and therapeutics of curcumin in health and disease. Advanc in Experim Medi Biol 2007; p. 995.
[227]
Vadhan VS, Weber D, Giralt S, et al. Curcumin downregulates NF-jB and related genes in patients with multiple myeloma: results of a phase 1/2 study. Am Soc Hematol 2007.
[228]
Dhillon N, Aggarwal BB, Li L, et al. Phase II trial of curcumin (diferuloyl methane), an NF-jB inhibitor, in patients with advanced pancreatic cancer. J Clin Oncol 2006; 24: 14151.
[229]
Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003; 171(7): 3863-71.
[230]
Aggarwal BB, Bhatt ID, Ichikawa H, et al. Curcumin-Biological and Medicinal Properties. Boca Raton, FL: The CRC Press 2006; pp. 297-368.
[231]
Wang Z, Zhang Y, Banerjee S, Li Y, Sarkar FH. Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 2006; 106(11): 2503-13.
[232]
Park CH, Hahm ER, Park S, Kim HK, Yang CH. The inhibitory mechanism of curcumin and its derivative against beta-catenin/Tcf signaling. FEBS Lett 2005; 579(13): 2965-71.
[233]
Jaiswal AS, Marlow BP, Gupta N, Narayan S. Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 2002; 21(55): 8414-27.
[234]
Balasubramanyam K, Varier RA, Altaf M, et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 2004; 279(49): 51163-71.
[235]
Marcu MG, Jung YJ, Lee S, et al. Curcumin is an inhibitor of p300 histone acetylatransferase. Med Chem 2006; 2(2): 169-74.
[236]
Pendurthi UR, Rao LV. Suppression of transcription factor Egr-1 by curcumin. Thromb Res 2000; 97(4): 179-89.
[237]
Chen A, Xu J, Johnson AC. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene 2006; 25(2): 278-87.
[238]
Fu Y, Zheng S, Lin J, Ryerse J, Chen A. Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol Pharmacol 2008; 73(2): 399-409.
[239]
Kuhad A, Chopra K. Curcumin attenuates diabetic encephalopathy in rats: behavioral and biochemical evidences. Eur J Pharmacol 2007; 576(1-3): 34-42.
[240]
Gulcubuk A, Altunatmaz K, Sonmez K, et al. Effects of curcumin on tumour necrosis factor-alpha and interleukin-6 in the late phase of experimental acute pancreatitis. J Vet Med A Physiol Pathol Clin Med 2006; 53(1): 49-54.
[241]
Dinarello CA. The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev 2006; 25(3): 307-13.
[242]
Cho JW, Lee KS, Kim CW. Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. Int J Mol Med 2007; 19(3): 469-74.
[243]
Ranjan D, Chen C, Johnston TD, Jeon H, Nagabhushan M. Curcumin inhibits mitogen stimulated lymphocyte proliferation, NFkappaB activation, and IL-2 signaling. J Surg Res 2004; 121(2): 171-7.
[244]
Kobayashi T, Hashimoto S, Horie T. Curcumin inhibition of Dermatophagoides farinea-induced interleukin-5 (IL-5) and granulocyte macrophage-colony stimulating factor (GM-CSF) production by lymphocytes from bronchial asthmatics. Biochem Pharmacol 1997; 54(7): 819-24.
[245]
Fahey AJ, Adrian Robins R, Constantinescu CS. Curcumin modulation of IFN-beta and IL-12 signalling and cytokine induction in human T cells. J Cell Mol Med 2007; 11(5): 1129-37.
[246]
Grandjean-Laquerriere A, Antonicelli F, Gangloff SC, Guenounou M, Le Naour R. UVB-induced IL-18 production in human keratinocyte cell line NCTC 2544 through NF-kappaB activation. Cytokine 2007; 37(1): 76-83.
[247]
Chen YR, Tan TH. Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 1998; 17(2): 173-8.
[248]
Weir NM, Selvendiran K, Kutala VK, et al. Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther 2007; 6(2): 178-84.
[249]
Kohl NE, Omer CA, Conner MW, et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1995; 1(8): 792-7.
[250]
Arbiser JL, Klauber N, Rohan R, et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med 1998; 4(6): 376-83.
[251]
Gururaj AE, Belakavadi M, Venkatesh DA, Marmé D, Salimath BP. Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem Biophys Res Commun 2002; 297(4): 934-42.
[252]
Dean EJ, Ranson M, Blackhall F, Holt SV, Dive C. Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic. Cancer Treat Rev 2007; 33(2): 203-12.
[253]
Liu JY, Lin SJ, Lin JK. Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13-acetate in NIH 3T3 cells. Carcinogenesis 1993; 14(5): 857-61.
[254]
Kumar A, Dhawan S, Mukhopadhyay A, Aggarwal BB. Human immunodeficiency virus-1-tat induces matrix metalloproteinase-9 in monocytes through protein tyrosine phosphatase-mediated activation of nuclear transcription factor NF-kappaB. FEBS Lett 1999; 462(1-2): 140-4.
[255]
Korutla L, Cheung JY, Mendelsohn J, Kumar R. Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. Carcinogenesis 1995; 16(8): 1741-5.
[256]
Mohan R, Sivak J, Ashton P, et al. Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J Biol Chem 2000; 275(14): 10405-12.
[257]
Yang X, Thomas DP, Zhang X, et al. Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation. Arterioscler Thromb Vasc Biol 2006; 26(1): 85-90.
[258]
Zhou Y, Zheng S, Lin J, Zhang QJ, Chen A. The interruption of the PDGF and EGF signaling pathways by curcumin stimulates gene expression of PPARgamma in rat activated hepatic stellate cell in vitro. Lab Invest 2007; 87(5): 488-98.
[259]
Nakamura K, Yasunaga Y, Segawa T, et al. Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. Int J Oncol 2002; 21(4): 825-30.
[260]
Verma SP, Goldin BR, Lin PS. The inhibition of the estrogenic effects of pesticides and environmental chemicals by curcumin and isoflavonoids. Environ Health Perspect 1998; 106(12): 807-12.
[261]
Ohene-Abuakwa Y, Pignatelli M. Adhesion molecules as diagnostic tools in tumor pathology. Int J Surg Pathol 2000; 8(3): 191-200.
[262]
Gupta B, Ghosh B. Curcuma longa inhibits TNF-alpha induced expression of adhesion molecules on human umbilical vein endothelial cells. Int J Immunopharmacol 1999; 21(11): 745-57.
[263]
Chun KS, Keum YS, Han SS, Song YS, Kim SH, Surh YJ. Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF-kappaB activation. Carcinogenesis 2003; 24(9): 1515-24.
[264]
Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 2007; 67(8): 3853-61.
[265]
Aggarwal BB, Shishodia S, Takada Y, et al. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 2005; 11(20): 7490-8.
[266]
Skommer J, Wlodkowic D, Pelkonen J. Gene-expression profiling during curcumin-induced apoptosis reveals downregulation of CXCR4. Exp Hematol 2007; 35(1): 84-95.
[267]
el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75(4): 817-25.
[268]
Liu E, Wu J, Cao W, et al. Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma. J Neurooncol 2007; 85(3): 263-70.
[269]
Shankar S, Srivastava RK. Involvement of Bcl-2 family members, phosphatidylinositol 3′-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int J Oncol 2007; 30(4): 905-18.
[270]
Sharma RA, McLelland HR, Hill KA, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001; 7(7): 1894-900.
[271]
Garcea G, Berry DP, Jones DJ, et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 2005; 14(1): 120-5.
[272]
Plummer SM, Hill KA, Festing MF, Steward WP, Gescher AJ, Sharma RA. Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents. Cancer Epidemiol Biomarkers Prev 2001; 10(12): 1295-9.
[273]
Kuttan R, Sudheeran PC, Josph CD. Turmeric and curcumin as topical agents in cancer therapy. Tumori 1987; 73(1): 29-31.
[274]
Durgaprasad S, Pai CG, Vasanthkumar J, Alvres JF, Namitha S. A pilot study of the antioxidant effect of curcumin in tropical pancreatitis. Indian J Med Res 2005; 122(4): 315-8.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 2
Year: 2019
Page: [92 - 113]
Pages: 22
DOI: 10.2174/1574885513666180907103659
Price: $65

Article Metrics

PDF: 51
HTML: 4
EPUB: 3
PRC: 3